1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging
(
- Contribution to journal › Article
- 2021
-
Mark
Deep learning-based classification and structure name standardization for organ at risk and target delineations in prostate cancer radiotherapy
(
- Contribution to journal › Article
-
Mark
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
(
- Contribution to journal › Article
- 2019
-
Mark
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer : 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
(
- Contribution to journal › Article
- 2016
-
Mark
Bone-targeted novel cytotoxic polybisphosphonate conjugate in castration-resistant prostate cancer : A multicenter phase 1 study
(
- Contribution to journal › Article
-
Mark
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer : A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice
(
- Contribution to journal › Article
- 2014
-
Mark
Change in prostate volume during extreme hypo-fractionation analysed with MRI.
(
- Contribution to journal › Article